{"nctId":"NCT00635648","briefTitle":"A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)","startDateStruct":{"date":"2008-01"},"conditions":["Fungal Infection"],"count":63,"armGroups":[{"label":"Caspofungin 50 mg Intravenous (IV)","type":"EXPERIMENTAL","interventionNames":["Drug: caspofungin acetate"]}],"interventions":[{"name":"caspofungin acetate","otherNames":["MK0991","Cancidas®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has a confirmed diagnosis of esophageal candidiasis or invasive candidiasis for whom IV antifungal therapy is appropriate\n* FOR ESOPHAGEAL CANDIDIASIS\n* Participant has endoscopic evidence of esophageal candidiasis\n* Participant has disease documented by symptoms consistent with esophageal candidiasis and positive stain or wetmount KOH of brushing or biopsy from endoscopy followed by positive culture for Candida or positive histopathologic evidence of Candida infection\n* FOR INVASIVE CANDIDIASIS\n* Participant has at least 1 positive culture of a Candida species from blood or other normally sterile body site obtained within 96 hours of study entry\n* Participant has clinical evidence of infection within 96 hours before study entry\n* Temperature \\>100\\^◦F (37.8\\^◦F) on 2 occasions at least 4 hours apart or 1 determination of \\>101\\^◦F (38.3\\^◦F) or clinically significant hypothermia \\<96.8\\^◦F (36.0\\^◦C)\n* Systolic blood pressure \\<90 or ≥30 mm Hg decrease in systolic blood pressure from the participant's normal baseline\n* Signs of inflammation at a site infected with Candida\n\nExclusion Criteria:\n\n* Participant has any of the following abnormal laboratory values: International Normalization Ratio (INR) \\>1.6 or, if participant is receiving anticoagulants, INR \\>4.0; bilirubin \\>5 times the upper limit of normal range;\n\naspartate aminotransferase (AST, or serum glutamic oxaloacetic transaminase \\[SGOT\\]) or alanine aminotransferase (ALT, or serum glutamic pyruvic transaminase \\[SGPT\\]) \\>5 times the upper limit of normal range\n\n* FOR ESOPHAGEAL CANDIDIASIS\n* Participant has Candida disease limited to the oropharynx\n* Participant has another cause of esophagitis or has clearly defined ulcers on endoscopy with high likelihood of another non-Candida pathogen\n* Participant has other esophageal pathology on endoscopy that is unrelated to acute esophageal candidiasis\n* FOR INVASIVE CANDIDIASIS\n* Participant has evidence of infection limited to a positive culture for Candida from urine, sputum, catheter tip, indwelling drain, or mucosal or superficial skin surface\n* Participant has suspected Candida endocarditis, osteomyelitis, or meningitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With One or More Drug-related Serious Adverse Events","description":"A serious adverse event is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the patient and may require medical intervention.\n\nA drug-related adverse event is a determination by the investigator physician that the study drug caused the event based on exposure, time course, likely cause, dechallenge (event resolved/improved when drug was discontinued), rechallenge (event resolved/improved when drug was re-introduced), and consistency with the drug profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With One or More Drug-related Adverse Events","description":"A drug-related adverse event is a determination by the investigator physician that the study drug caused the event based on exposure, time course, likely cause, dechallenge (event resolved/improved when drug was discontinued), rechallenge (event resolved/improved when drug was re-introduced), and consistency with the drug profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Due to a Drug-related Adverse Event","description":"A drug-related adverse event is a determination by the investigator physician that the study drug caused the event based on exposure, time course, likely cause, dechallenge (event resolved/improved when drug was discontinued), rechallenge (event resolved/improved when drug was re-introduced), and consistency with the drug profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Favorable Overall Response for Esophageal Candidiasis or Invasive Candidiasis","description":"Efficacy response for esophageal candidiasis was based on clinical and endoscopic criteria; favorable responses included complete and partial improvement in symptoms and endoscopic lesions.\n\nEfficacy response for invasive candidiasis was based on microbiological and clinical assessments; favorable responses required both favorable microbiological response (i.e., eradication or presumptive eradication based on symptoms, physical exam, and non-invasive tests) and complete or partial clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":63},"commonTop":["Blood Potassium Decreased","Alanine Aminotransferase Increased","Aspartate Aminotransferase Increased","Blood Bilirubin Increased","Blood Creatinine Increased"]}}}